Here’s a bold statement: The world of lymphoma research is on the brink of a revolution, and it’s all thanks to groundbreaking work like the new Lancet series on T-cell and NK-cell lymphomas. But here’s where it gets controversial—while these advancements are undeniably transformative, they also raise questions about accessibility and the pace of global adoption. Let’s dive in.
Wee Joo Chng, Vice President of Biomedical Science Research at the National University of Singapore and Group Director of Research Office at the National University Health System of Singapore, recently shared an exciting update on LinkedIn (https://www.linkedin.com/posts/wee-joo-chng-69b0b9146review-on-nktl-in-lancet-ugcPost-7395284430975660033-JMRe?utmsource=share&utmmedium=memberdesktop&rcm=ACoAAGFuiLsBxfZV7xg5LM9u4NuqwcPDbBJ9A). He highlighted a meticulously crafted review published during Lymphoma Awareness Month in September, focusing on the molecular characterization of Extranodal Natural Killer/T-cell lymphoma. This piece, authored by William Wee Lee Chan in collaboration with Siok Bian Ng and beautifully illustrated by Diego A., is part of a larger series across the Lancet journals. And this is the part most people miss—the series isn’t just about presenting data; it’s about reshaping how we understand and treat these complex diseases.
The first article, published in The Lancet Regional Health – Western Pacific, titled ‘Epidemiology of mature T-cell and NK-cell neoplasms: East and West’, explores the geographical disparities in these cancers. Authors Yok-Lam Kwong, Huilai Zhang, Xianhuo Wang, and Eric Tse shed light on why certain regions bear a higher burden of these diseases. You can read the full article here: (https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(25)00185-3/fulltext).
The second article, featured in The Lancet Hematology, is titled ‘Emerging therapeutic strategies for mature T-cell and natural killer-cell lymphomas’. Written by Prof Eric Tse, Prof Christiane Querfeld, Prof Kenji Ishitsuka, and Prof Yok-Lam Kwong, it delves into cutting-edge treatments that could redefine patient outcomes. Check it out here: (https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/abstract). Here’s the kicker—these therapies are not just theoretical; they’re already showing promise in clinical trials, but how quickly can they reach patients worldwide?
What’s even more exciting is that these articles were penned by Wee Joo Chng’s close collaborators, Profs Kwong Yok-Lam and Eric Tse from The University of Hong Kong. This project also led to a fascinating podcast (https://www.buzzsprout.com/1564352/episodes/17790269) and an accompanying commentary in The Lancet Hematology, titled ‘Advancing understanding of mature T-cell and natural killer-cell lymphomas’ by Shunan Qi and Qingqing Cai. Read it here: (https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00237-6/abstract).
Now, here’s a thought-provoking question: As we celebrate these scientific breakthroughs, are we doing enough to ensure equitable access to these advancements across the globe? The research is undeniably impressive, but its true impact will be measured by how many lives it touches. What do you think? Share your thoughts in the comments below.
For more insightful posts featuring Wee Joo Chng, visit OncoDaily: (https://oncodaily.com/tag/wee-joo-chng).
